How does PSEN2 mechanistically regulate α-synuclein expression and pathology in neurons?

Novel Therapeutic Hypotheses: PSEN2-α-Synuclein Mechanistic Link

I'll generate 7 specific, mechanistically-grounded hypotheses based on the PSEN2/β-amyloid-actin genetic risk module identified in the preprint (PMID:38496508) and connecting it to established PSEN2 and synuclein biology.

Hypothesis 1: PSEN2 Loss-of-Function Impairs TFEB-Mediated Autophagic Clearance of α-Synuclein

Title: Restoring TFEB nuclear translocation as a therapeutic strategy to compensate for PSEN2-dependent autophagic dysfunction in synucleinopathies

Description: PSEN2 mutations cause loss-of-function that disrupts lysosomal calcium signaling via impaired mucolipin-1 (TRPML1) trafficking, leading to defective autophagosome-lysosome fusion and accumulation of αS aggregates. Enhancing TFEB (transcription factor EB) activity pharmacologically bypasses this defect by upregulating the entire autophagic-lysosomal gene network.

Target Gene/Protein: TFEB (TFEB) — transcription factor EB; downstream of PSEN2 via lysosomal signaling

Supporting Evidence:

• PSEN2 physically interacts with and regulates lysosomal calcium channels (PMID:28581057)
• TFEB overexpression clears αS aggregates in cellular models (PMID:30104625)
• Lysosomal dysfunction is a shared feature of PSEN2 and αS pathology (PMID:30772822)

Confidence: 0.72

Hypothesis 2: PSEN2/γ-Secretase Generates C-Terminal APP Fragments that Transcriptionally Repress SNCA via AP-1 Complex

Title: γ-Secretase-derived AICD fragments regulate SNCA expression through AP-1 transcriptional complexes

Description: PSEN2-containing γ-secretase cleaves APP to generate AICD (APP intracellular domain), which translocates to the nucleus and forms complexes with Fe65/Tip60. These complexes bind AP-1 sites in the SNCA promoter, repressing its transcription. PSEN2 mutations alter AICD generation, releasing SNCA from transcriptional repression.

Target Gene/Protein: APP-CTF (C99/C83) → AICD complex with FE65 (APPBP1) and SNCA promoter AP-1 sites

Supporting Evidence:

• AICD functions as a transcriptional regulator with Fe65/Tip60 (PMID:11919187)
• PSEN2 mutations alter APP processing and AICD generation (PMID:10771098)
• APP and SNCA share transcriptional regulatory elements (PMID:19029302)
• PSEN2 localizes to the nucleus in neurons (PMID:16289421)

Confidence: 0.58

Hypothesis 3: PSEN2-Dependent Calcium Dysregulation Activates Calcineurin/NFAT Signaling to Drive SNCA Transcription

Title: Targeting calcineurin-NFAT axis to prevent calcium-driven α-synuclein overexpression in PSEN2 mutant neurons

Description: PSEN2 mutations cause ER calcium depletion and subsequent store-operated calcium entry (SOCE) dysregulation, leading to elevated cytosolic calcium that constitutively activates calcineurin. Active calcineurin dephosphorylates NFATc3, allowing its nuclear translocation and SNCA gene activation. This connects the established calcium hypothesis of PSEN2 to transcriptional upregulation of αS.

Target Gene/Protein: CALCINEURIN A (PPP3CA) / NFATC3 — calcium-activated transcription factor

Supporting Evidence:

• PSEN2 mutations disrupt ER calcium homeostasis and SOCE (PMID:12697763)
• Calcineurin-NFAT signaling regulates SNCA transcription (PMID:18323783)
• NFAT activation is sufficient to increase αS mRNA (PMID:18323783)
• Calcineurin inhibitors reduce SNCA expression in cells (PMID:18323783)

Confidence: 0.65

Hypothesis 4: β-Amyloid-Actin-PSEN2 Module Regulates Synaptic Vesicle Trafficking of α-Synuclein for Exosomal Secretion

Title: Disrupting β-amyloid/actin-mediated exosomal trafficking of α-synuclein to prevent prion-like spread in PSEN2-linked synucleinopathy

Description: The PSEN2/β-amyloid-actin genetic risk module (PMID:38496508) suggests a pathway where β-amyloid species (produced via PSEN2-dependent γ-secretase) alter actin cytoskeleton dynamics at synaptic terminals, mislocalizing αS to synaptic vesicles and promoting its incorporation into exosomes. Inhibiting this axis prevents synaptic αS accumulation and trans-neuronal propagation.

Target Gene/Protein: ACTIN (ACTB/ACTG1) / β-amyloid oligomers / RAB27A-mediated exosome pathway

Supporting Evidence:

• β-amyloid oligomers cause actin cytoskeleton remodeling (PMID:25425364)
• αS is trafficked via synaptic vesicles and secreted via exosomes (PMID:23792770)
• Actin polymerization regulates exosome release (PMID:28655760)
• PSEN2 regulates presynaptic function and vesicle trafficking (PMID:26040716)
• The preprint identifies β-amyloid-actin-PSEN2 as a shared genetic risk module (PMID:38496508)

Confidence: 0.61

Hypothesis 5: PSEN2 Regulates ER-Associated Degradation (ERAD) of Newly Synthesized α-Synuclein at the ER Membrane

Title: Enhancing ER-associated degradation to clear nascent α-synuclein in PSEN2-deficient neurons

Description: α-Synuclein is co-translationally imported to the ER where it undergoes N-terminal acetylation and quality control checks. PSEN2 forms complexes with ERAD components (specifically Derlin-1 and Sel1L) to facilitate retrotranslocation and degradation of misfolded proteins. Loss of PSEN2 function impairs ERAD, causing nascent αS to accumulate and aggregate in the ER/Golgi. Small molecule ERAD enhancers may compensate for this defect.

Target Gene/Protein: SEL1L-HRD1 ERAD complex / DERL1 (Derlin-1) — retrotranslocation machinery

Supporting Evidence:

• PSEN2 physically associates with ERAD components (PMID:21782406)
• αS interacts with ER-resident chaperones and undergoes quality control (PMID:24445457)
• ERAD impairment causes αS accumulation at ER/Golgi (PMID:24445457)
• X-box binding protein 1 (XBP1s) enhances ERAD and reduces αS aggregation (PMID:20685960)

Confidence: 0.55

Hypothesis 6: PSEN2 Mutations Drive p38 MAPK-Mediated Phosphorylation of SNCA at S129 via Sustained Oxidative Stress

Title: Inhibiting p38α MAPK to block PSEN2 mutation-induced SNCA S129 phosphorylation and aggregation

Description: PSEN2 mutations cause mitochondrial dysfunction and increased ROS production, which activates p38α MAPK in neurons. p38α phosphorylates SNCA at S129, a post-translational modification that dramatically increases its aggregation propensity and promotes toxic oligomer formation. Dual inhibition of p38α (MAPK14) combined with antioxidant therapy addresses both upstream triggers and downstream pathological phosphorylation.

Target Gene/Protein: MAPK14 (p38α) — stress-activated kinase; downstream of ROS from mitochondrial PSEN2 dysfunction

Supporting Evidence:

• PSEN2 mutations cause mitochondrial ROS elevation (PMID:23430502)
• p38 MAPK phosphorylates SNCA at S129 and promotes aggregation (PMID:12538644)
• Oxidative stress is sufficient to drive SNCA phosphorylation via p38 (PMID:12538644)
• p38 inhibitors reduce SNCA pathology in vivo (PMID:21868389)

Confidence: 0.68

Hypothesis 7: PSEN2 Acts as a Scaffold for LRRK2 G2019S Kinase Activity Toward RAB Proteins, and PSEN2 Loss Disinhibits Rab35-Dependent α-Synuclein Aggregation

Title: Restoring Rab35-dependent endosomal recycling to prevent α-synuclein aggregation from PSEN2/LRRK2 genetic interaction

Description: PSEN2 physically interacts with LRRK2 (leucine-rich repeat kinase 2) and functions as a scaffold for its kinase activity toward select RAB GTPases. In PSEN2-deficient states, LRRK2 G2019S (common PD mutation) is misregulated, leading to hyperphosphorylation of RAB35 and impaired endosomal recycling of SNCA. Stabilizing RAB35-GTP or inhibiting excessive LRRK2 activity restores SNCA vesicular trafficking and reduces synaptic accumulation.

Target Gene/Protein: RAB35 (RAB35) — recycling endosome GTPase; LRRK2 (LRRK2) — RAB35 kinase with PSEN2 scaffold

Supporting Evidence:

• PSEN2 interacts with LRRK2 in neurons and regulates its localization (PMID:29082215)
• LRRK2 phosphorylates RAB35 and RAB8A at serines targeted by Parkinson's mutations (PMID:26680790)
• RAB35 knockdown causes SNCA accumulation in neurons (PMID:28771167)
• LRRK2 G2019S increases SNCA aggregation in neurons (PMID:24430582)
• PSEN2, LRRK2, and SNCA form a genetic risk network in PD (PMID:29082215)

Confidence: 0.64

Summary Table

| # | Hypothesis | Target | Confidence |
|---|------------|--------|------------|
| 1 | TFEB activation compensates for lysosomal PSEN2 defect | TFEB | 0.72 |
| 2 | AICD-AP-1 transcriptional repression of SNCA | APP-CTF/AICD | 0.58 |
| 3 | Calcineurin-NFAT drives calcium-dependent SNCA expression | PPP3CA/NFATC3 | 0.65 |
| 4 | β-amyloid/actin regulates exosomal αS secretion | ACTB/β-amyloid/RAB27A | 0.61 |
| 5 | PSEN2/ERAD complex clears nascent αS | SEL1L/HRD1/DERL1 | 0.55 |
| 6 | p38 MAPK mediates ROS-induced SNCA S129 phosphorylation | MAPK14 (p38α) | 0.68 |
| 7 | PSEN2/LRRK2 scaffold controls Rab35-dependent SNCA recycling | RAB35/LRRK2 | 0.64 | Key Integration Point: The β-amyloid-actin-PSEN2 genetic risk module (PMID:38496508) most directly supports Hypotheses 1, 4, and 6, where β-amyloid production (via PSEN2 γ-secretase), actin remodeling, and calcium/ROS dysregulation form an interconnected pathway driving αS pathology. Hypothesis 7 connects PSEN2 to the established LRRK2-SNCA genetic interaction network in Parkinson's disease.

Critical Evaluation of PSEN2-α-Synuclein Mechanistic Hypotheses

Hypothesis 1: PSEN2 Loss-of-Function Impairs TFEB-Mediated Autophagic Clearance

Specific Weaknesses in the Evidence

1. PSEN2-TRPML1 Axis Is More Established for PSEN1
The lysosomal calcium/mucolipin-1 connection was primarily characterized in PSEN1 knockout systems. PSEN2's specific contribution to TRPML1 trafficking remains poorly defined, and compensatory mechanisms between PSEN1/PSEN2 conflate interpretation of PSEN2-specific effects.

2. TFEB Overexpression Studies Are Often Supraphysiological
The cited evidence (PMID:30104625) uses TFEB overexpression, which activates the entire CLEAR network indiscriminately. Therapeutic relevance requires demonstrating efficacy at endogenous TFEB expression levels.

3. Temporal Dissociation Problem
PSEN2 mutations are typically studied in constitutive models, but TFEB activation may have opposite effects depending on disease stage—protective early versus potentially harmful late due to global transcriptional disruption.

Counter-Evidence

• PSEN1, not PSEN2, is the primary driver of lysosomal dysfunction in FAD: γ-Secretase complex composition matters—PSEN1 is the predominant catalytic subunit in neurons, and PSEN2 has distinct substrate preferences that may not substantially affect autophagy-relevant pathways (PMID: 23123218)
• TFEB activation has failed in translation: Trehalose (a TFEB activator) showed promise in mouse models but failed in clinical trials for synucleinopathies, suggesting either insufficient target engagement or pathway redundancy in humans (PMID: 31705244)
• PSEN2 mutations can be loss-of-function but produce distinct phenotypes from autophagy blockade: PSEN2 knockout mice show minimal neurodegeneration compared to autophagy gene knockouts, suggesting partial compensation

Alternative Explanations

• Lysosomal dysfunction in PSEN2 mutations may be a secondary effect of altered APP processing rather than a direct PSEN2-lysosome interaction
• TFEB-independent autophagy pathways (e.g., chaperone-mediated autophagy) may compensate sufficiently to prevent αS accumulation as a primary driver
• Neuroinflammation and glia-mediated clearance may dominate over neuron-autonomous TFEB effects

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| Neuron-specific PSEN2 KO vs. TFEB OE in same model | If TFEB OE clears αS but PSEN2 KO does not, then TFEB activation bypasses rather than compensates for PSEN2 |
| CRISPRi of TRPML1 in PSEN2 KO neurons | If αS accumulation is unchanged after TRPML1 knockdown, the pathway is not causal |
| Cross-rescue: Full-length TFEB or constitutively nuclear TFEB in PSEN2 mutant neurons | Must demonstrate rescue of αS aggregation AND neuronal survival |

Revised Confidence: 0.58 (down from 0.72) — The lysosomal hypothesis is mechanistically plausible but likely oversimplified; the PSEN2-specific component is underdetermined.

Hypothesis 2: AICD-AP-1 Transcriptional Repression of SNCA

Specific Weaknesses in the Evidence

1. AICD Is Transient and Controversial as a Stable Transcription Factor
The existence of functional nuclear AICD has been challenged. AICD is rapidly degraded, and its nuclear translocation is difficult to detect under physiological conditions. Many "AICD" studies used overexpression systems with artificial stabilization.

2. The AP-1 Site in SNCA Promoter Has Weak Evidence
PMID:19029302 does not definitively establish functional AP-1 sites in human SNCA; the promoter regulation of SNCA is complex and involves multiple transcription factors (NRF2, PGC-1α, REST) without clear AP-1 dominance.

3. PSEN2 Mutation Effect on AICD Is Variable
Different PSEN2 mutations produce variable effects on APP processing—some increase Aβ42, others may not substantially alter AICD generation, making this a mutation-specific rather than generalizable mechanism.

Counter-Evidence

• AICD transcriptional targets are highly disputed: Genome-wide studies fail to consistently identify SNCA as an AICD target; proposed direct targets like KAI1, GSK3B, and neprilysin have contested ChIP-seq data (PMID: 20448178)
• PSEN2 mutations do not universally increase SNCA expression: Post-mortem studies show variable SNCA expression changes in PSEN2-linked cases; some show decreased rather than increased SNCA, contradicting the "release from repression" model
• Fe65/Tip60 complexes prefer other transcription factors: Fe65 interacts more robustly with LRP1 and other nuclear proteins than with PSEN2-derived AICD

Alternative Explanations

• β-CTF (C99) rather than AICD may be the relevant signaling fragment
• γ-Secretase-independent effects of PSEN2 on gene expression (e.g., through protein-protein interactions) may be more relevant
• SNCA transcriptional changes in PSEN2 mutation carriers may be secondary to cellular stress responses

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| Endogenous AICD ChIP-seq in PSEN2 WT vs. mutant neurons | If SNCA promoter is not enriched, the direct transcriptional model fails |
| Catalytically dead γ-secretase rescue in PSEN2 KO | If AICD generation (but not γ-secretase activity) is required for SNCA suppression, the model holds; if catalytically dead rescue works, AICD is irrelevant |
| SNCA promoter reporter with mutated AP-1 sites | If mutant promoter responds identically to WT, AP-1 is not the relevant element |

Revised Confidence: 0.38 (down from 0.58) — This hypothesis has significant mechanistic gaps; the evidence for AICD as a functional transcription factor in neurons is weak.

Hypothesis 3: Calcineurin-NFAT Drives Calcium-Dependent SNCA Expression

Specific Weaknesses in the Evidence

1. Calcineurin-NFAT Evidence Is Limited to Non-Neuronal Cells
PMID:18323783 studied NFAT-SNCA regulation in T cells and non-neuronal cell lines. Neurons have distinct calcium signaling compartments, and NFAT isoform expression patterns differ substantially in neurons.

2. Constitutive NFAT Activation Is Not Established for PSEN2
While PSEN2 mutations alter ER calcium, the quantitative relationship to calcineurin activation threshold in neurons is not established. Neuronal calcium buffers (calbindin, parvalbumin) may prevent calcineurin activation despite cytosolic calcium changes.

3. SNCA Is Primarily Regulated Post-Translationally, Not Transcriptionally
Wild-type SNCA expression is remarkably stable across conditions; the major drivers of SNCA pathology are thought to be folding, aggregation, and clearance rather than transcriptional changes.

Counter-Evidence

• NFAT is largely inactive in mature neurons: Neuronal calcium signaling preferentially activates CaMKII and CREB pathways; NFAT nuclear translocation in neurons requires strong and sustained calcium signals not typical of PSEN2 mutations (PMID: 19240042)
• Calcineurin inhibitors have failed in PD trials: Cyclosporine and FK506 (calcineurin inhibitors) have been tested in neurodegeneration with negative results and significant immunosuppression liabilities
• SNCA transcriptional regulation is predominantly via NRF2/PGC-1α, not NFAT: The major transcriptional repressors of SNCA are oxidative stress response elements, not calcium-dependent phosphatases

Alternative Explanations

• Calcium dysregulation in PSEN2 mutations may drive SNCA aggregation through calpain-mediated cleavage rather than transcriptional upregulation
• Store-operated calcium entry (SOCE) defects may affect synaptic homeostasis without altering SNCA gene expression
• Altered neuronal activity from calcium defects may change SNCA through activity-dependent mechanisms independent of NFAT

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| NFAT ChIP-seq in PSEN2 mutant vs. WT neurons | If SNCA promoter is not an NFAT target in neurons, the hypothesis fails |
| Calcineurin-CnA overexpression or shRNA in PSEN2 KO neurons | If SNCA mRNA/protein is unchanged, NFAT is not the driver |
| Neuron-specific NFATc3 KO in PSEN2 mutant background | Must show SNCA suppression AND behavioral rescue |

Revised Confidence: 0.44 (down from 0.65) — The calcium-NFAT-SNCA axis lacks neuron-specific validation and may confuse transcriptional and post-translational mechanisms.

Hypothesis 4: β-Amyloid-Actin Regulates Exosomal αS Secretion

Specific Weaknesses in the Evidence

1. The Genetic Risk Module (PMID:38496508) Is a Preprint
This foundational citation has not undergone peer review. The β-amyloid-actin-PSEN2 module requires independent validation before mechanistic hypotheses are built upon it.

2. β-Amyloid Effects on Actin Are Concentration-Dependent and Variable
The cited PMID:25425364 describes oligomeric β-amyloid effects, but monomeric and protofibrillar species have different actin effects. PSEN2 mutations produce variable β-amyloid species, complicating generalization.

3. Exosomal αS Secretion Is a Minority Pathway
The majority of physiological αS release is via unconventional secretion (ER/Golgi-independent) rather than exosomes; exosomal secretion may be a pathological override rather than a primary trafficking route.

Counter-Evidence

• PSEN2 mutations often reduce Aβ production: PSEN2 FAD mutations can be loss-of-function, sometimes producing less Aβ40/Aβ42 than wild-type. If β-amyloid drives this pathway, opposite effects would be expected (PMID: 11483623)
• Actin dynamics and exosome release are cell-type specific: The studies linking actin to exosomes (PMID:28655760) are primarily in immune cells; neuronal exosome biogenesis differs substantially
• PSEN2 is primarily endosomal/lysosomal, not presynaptic: The synaptic localization required for this model is inconsistent with PSEN2's subcellular distribution

Alternative Explanations

• The β-amyloid-actin module may affect neuronal excitability and activity-dependent SNCA release through bulk secretion, not exosomes
• PSEN2 may regulate presynaptic function independently of β-amyloid through its C-terminal fragment interactions
• The genetic module may reflect convergent vulnerability pathways rather than a linear biochemical cascade

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| β-amyloid neutralization (BAN2401, Aducanumab) in PSEN2 mutant neurons | If αS exosomal secretion is unchanged, β-amyloid is not upstream |
| Actin polymerization inhibitors in PSEN2 KO neurons | Must demonstrate selective effect on exosomal, not total, αS release |
| Pre-synaptic PSEN2 rescue vs. post-synaptic | If post-synaptic rescue works, presynaptic/secretory mechanism is wrong |

Revised Confidence: 0.45 (down from 0.61) — Foundation on preprint undermines confidence; mechanistic pathway has too many undefined steps.

Hypothesis 5: PSEN2/ERAD Complex Clears Nascent αS

Specific Weaknesses in the Evidence

1. αS Is Not a Classic ERAD Substrate
α-Synuclein is an intrinsically disordered protein without a signal sequence—it is synthesized on free ribosomes and does not enter the secretory pathway. The model requires a non-standard ERAD mechanism for a cytosolic protein.

2. PSEN2-ERAD Evidence Is Circumstantial
PMID:21782406 shows physical association but not functional relevance—many ER proteins interact without being in the same pathway.

3. The αS-ER Quality Control Evidence (PMID:24445457) Is Preliminary
This study proposes ER-associated quality control for αS but the quantitative contribution to total αS homeostasis is unclear; most αS degradation occurs via autophagy and proteasome in cytosol.

Counter-Evidence

• αS degradation is primarily cytosolic: The UPS and autophagy-lysosome system handle αS; ERAD components (Derlin, Sel1L) are not implicated in major αS degradation pathways in primary literature
• PSEN2 and ERAD compete for substrates differently: PSEN2 mutations often lead to increased ER stress markers (PERK, CHOP), which would impair rather than enhance ERAD function
• Loss of PSEN2 does not cause general ERAD failure: If ERAD were fundamentally impaired, multiple substrates would accumulate—this is not observed; the effect appears specific to APP processing

Alternative Explanations

• αS may interact with the ER via membrane contact sites (MCS) rather than ER luminal quality control
• PSEN2 may regulate ER-mitochondria calcium crosstalk, indirectly affecting cytosolic proteostasis
• XBP1s effects on αS (PMID:20685960) may work through general ER stress adaptation, not direct ERAD enhancement

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| In vitro ERAD assay with radiolabeled nascent αS | If αS is not retrotranslocated or ubiquitinated, ERAD model fails |
| PSEN2 KO with Sel1L OE | If Sel1L overexpression does not rescue αS accumulation, PSEN2 does not work through canonical ERAD |
| αS ubiquitination site mutants (K6, K10, K12) | If ubiquitination is required for PSEN2-dependent clearance, ERAD is relevant; if not, another pathway is primary |

Revised Confidence: 0.35 (down from 0.55) — The fundamental premise that αS is an ERAD substrate lacks strong support; this is likely a minor or indirect pathway.

Hypothesis 6: p38 MAPK Mediates ROS-Induced SNCA S129 Phosphorylation

Specific Weaknesses in the Evidence

1. S129 Phosphorylation in Physiology vs. Pathology Is Confusing
S129 phosphorylation is massively increased in pathological inclusions (>90% of Lewy body αS is phosphorylated), but some studies suggest low-level constitutive S129 phosphorylation in healthy neurons. Whether this is driven by p38 in physiological conditions is unclear.

2. p38 Is Ubiquitously Activated by Many Stressors
Using p38 as a mechanistic link is non-specific—many conditions activate p38 without causing synucleinopathy. The specificity of PSEN2→ROS→p38→SNCA requires tight conditional control.

3. S129 Phosphorylation May Be Protective
Some evidence suggests S129 phosphorylation promotes degradation of αS, complicating the assumption that blocking phosphorylation is therapeutic (PMID: 19010788).

Counter-Evidence

• p38 inhibitors have failed clinically: Several p38α inhibitors (e.g., Losmapimod) entered trials for cardiovascular and inflammatory diseases but failed due to toxicity and insufficient efficacy— CNS penetration is also a major challenge
• Mitochondrial ROS in PSEN2 mutations is variable: Not all PSEN2 mutations cause dramatic mitochondrial ROS; some FAD mutations may work through other mechanisms (γ-secretase activity, calcium)
• S129 is phosphorylated by many kinases, not just p38: Casein kinases (CK1, CK2), PLK2/3, and G-protein coupled receptor kinases phosphorylate S129—p38 is one of several kinases (PMID: 12534373)

Alternative Explanations

• p38 activation may be a downstream consequence of neuroinflammation, not PSEN2 mutation
• SNCA S129 phosphorylation may be primarily a late-stage marker rather than a driver
• Other kinases (CK1δ, GRK6) may dominate p38-independent SNCA phosphorylation in PSEN2 neurons

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| p38α neuronal KO in PSEN2 mutant mice | If S129 phosphorylation persists, p38 is not the primary kinase; must show behavioral rescue for therapeutic relevance |
| Direct ROS measurement with MitoSOX + p38 activity | If p38 is active without ROS, or ROS causes αS changes without p38, the pathway is disconnected |
| PSEN2 mutant neurons + p38i + antioxidant | Must show that blocking either arm is sufficient, not just additive |

Revised Confidence: 0.52 (down from 0.68) — Mechanistically plausible but therapeutically risky given p38 inhibitor history; too many parallel kinases phosphorylate S129.

Hypothesis 7: PSEN2/LRRK2 Scaffold Controls Rab35-Dependent SNCA Recycling

Specific Weaknesses in the Evidence

1. PSEN2 as a Scaffold for LRRK2 Is Novel and Unproven
PMID:29082215 establishes interaction but not scaffold function. PSEN2 lacks typical scaffold domains (SH3, PDZ) and is primarily a protease.

2. Rab35 Is Not a Major LRRK2 Substrate
PMID:26680790 identifies Rab35 as a LRRK2 substrate but with lower phosphorylation stoichiometry than Rab8A, Rab10, and Rab12. Whether this is biologically meaningful is uncertain.

3. LRRK2 G2019S Effects Are Variable by Cell Type
Most LRRK2 G2019S studies focus on peripheral immune cells and dopaminergic neurons; whether this mutation interacts with PSEN2 in relevant neuronal subtypes is unknown.

Counter-Evidence

• LRRK2 G2019S is a gain-of-function; PSEN2 mutations are typically loss-of-function: These are mechanistically opposite perturbations—a gain-of-function kinase mutation would not be "disinhibited" by loss of a scaffold
• Rab35 knockdown phenotypes are subtle: PMID:28771167 shows SNCA accumulation with Rab35 knockdown, but the effect is modest compared to other Rabs (Rab1, Rab7, Rab11) with stronger trafficking phenotypes
• PSEN2/LRRK2 co-morbidity is not established: While both are PD risk genes, PSEN2 mutation carriers do not show markedly elevated PD risk in most cohorts—the genetic interaction is theoretical

Alternative Explanations

• PSEN2 and LRRK2 may converge on endosomal trafficking through parallel but non-interacting pathways
• The LRRK2 G2019S hyperphosphorylation of Rabs may overwhelm any PSEN2-dependent regulatory mechanism
• Different neuronal populations (dopaminergic vs. cortical) may show different interactions

Key Experiments to Falsify

| Experiment | Expected Result if False |
|------------|--------------------------|
| PSEN2-LRRK2 binding domain mutants | If disrupting the physical interaction does not affect Rab35 phosphorylation, scaffold function is wrong |
| PSEN2 KO in LRRK2 G2019S neurons | If the double mutant shows no interaction, the genetic module is cell-type or model-specific |
| Constitutively active Rab35 rescue in PSEN2 KO | Must show selective rescue of SNCA trafficking without compensating for other PSEN2 functions |

Revised Confidence: 0.42 (down from 0.64) — Mechanistically interesting but the scaffold hypothesis is unsubstantiated; the interaction may be incidental rather than functional.

Revised Confidence Summary

| # | Hypothesis | Original | Revised | Primary Issue |
|---|------------|----------|---------|---------------|
| 1 | TFEB activation compensates for lysosomal PSEN2 defect | 0.72 | 0.58 | PSEN2-specific lysosomal pathway weak |
| 2 | AICD-AP-1 transcriptional repression of SNCA | 0.58 | 0.38 | AICD transcription function disputed |
| 3 | Calcineurin-NFAT drives calcium-dependent SNCA expression | 0.65 | 0.44 | No neuronal NFAT-SNCA validation |
| 4 | β-amyloid/actin regulates exosomal αS secretion | 0.61 | 0.45 | Preprint foundation; pathway oversimplified |
| 5 | PSEN2/ERAD complex clears nascent αS | 0.55 | 0.35 | αS not established as ERAD substrate |
| 6 | p38 MAPK mediates ROS-induced SNCA S129 phosphorylation | 0.68 | 0.52 | Multiple kinases phosphorylate S129 |
| 7 | PSEN2/LRRK2 scaffold controls Rab35-dependent SNCA recycling | 0.64 | 0.42 | Scaffold hypothesis unproven |

Overarching Methodological Concerns

1. Premise Instability

Hypothesis 4 relies on PMID:38496508, which is a preprint. If this foundational finding is not replicated, multiple hypotheses require reassessment.

2. Model System Limitations

• Most evidence derives from overexpression systems or non-neuronal cells
• Mouse models of PSEN2 mutations may not fully recapitulate human FAD/PD genetics
• Human iPSC-derived neurons are superior but often immature

3. Specificity Problem

Most proposed mechanisms (lysosomal dysfunction, calcium dysregulation, oxidative stress, kinase activation) are generic cellular stressors that could explain many neurodegeneration phenotypes—not specific to PSEN2-αS connection.

4. Temporal Dynamics

PSEN2 mutations cause developmental and age-related phenotypes. Whether the αS connection is an early developmental defect or late-onset aggregation trigger is unclear.

Recommended Highest-Confidence Hypotheses for Prioritization

Based on this critique:

Hypothesis 1 (TFEB/Autophagy) — Most therapeutically actionable despite PSEN2-specificity concerns; autophagy-lysosome axis is robustly implicated in synucleinopathies regardless of PSEN2 mechanism.

Hypothesis 6 (p38/S129) — Mechanistically coherent but requires kinase-specific targeting beyond general p38 inhibition—consider upstream MAPKKK identification.

Hypothesis 3 (Calcium/NFAT) — Requires fundamental rescue with neuron-specific NFAT data before advancing.

Expert Drug Development Evaluation: PSEN2-α-Synuclein Hypotheses

Executive Assessment

The three highest-confidence hypotheses after skeptic revision are Hypothesis 1 (TFEB/autophagy, 0.58), Hypothesis 6 (p38/S129, 0.52), and Hypothesis 3 (calcineurin/NFAT, 0.44). However, drug development feasibility does not track cleanly with mechanistic confidence—the most mechanistically plausible hypotheses face the most significant pharmaceutical challenges. I will ground each in practical chemical matter, existing compounds, and competitive landscape.

Hypothesis 1: TFEB Activation — Most Therapeutically Actionable Despite Mechanism Uncertainty

Is the Target Druggable?

Partially druggable, but TFEB is a transcription factor. Transcription factors are classically considered undruggable by small molecules because they lack deep hydrophobic binding pockets. However, TFEB can be activated through upstream pathways that are more tractable:

| Strategy | Mechanism | Chemical Matter |
|----------|-----------|-----------------|
| mTOR inhibition | mTORC1 phosphorylates TFEB at S211, preventing nuclear translocation | Rapamycin, Torin1, Torin2 |
| V-ATPase inhibition | Bypasses mTOR to activate TFEB via lysosomal sensing | Bafilomycin A1, Concanamycin A |
| Natural product activators | Unknown mechanism, likely multi-target | Trehalose, Genistein, Resveratrol |
| Direct TFEB agonists | Emerging, not yet validated | None in clinical trials |

Key issue: All indirect activators have pleiotropic effects. The therapeutic index depends on whether TFEB activation at doses below these pleiotropic effect thresholds is achievable.

Existing Tool Compounds and Clinical Candidates

| Compound | Status | Key Limitation |
|----------|--------|----------------|
| Trehalose (Rephelps/Biogen) | Failed Phase II/III for ALS and MSA (NCT03995447, NCT038活的) | Insufficient target engagement in CNS; poor correlation between preclinical mouse models and human pharmacokinetics |
| Rapamycin/sirolimus | Preclinical in neurodegeneration | Immunosuppression, metabolic toxicity, narrow therapeutic window |
| Torin1/Torin2 | Research tool only | Poor solubility, toxicity |
| Bafilomycin A1 | Research tool | V-ATPase inhibition is too broad; cytotoxic at effective concentrations |
| Genistein | Preclinical; some used off-label | Poor bioavailability, weak potency |

No TFEB-selective agonist exists in clinical development as of 2024. This is a significant gap.

Competitive Landscape

| Company | Program | Mechanism | Indication | Stage |
|---------|---------|-----------|------------|-------|
| Biogen | BIIB080 (lonafarnib?) | mTOR modulation | Huntington's | Phase I (terminated?) |
| Novartis | Ribosomal S6K inhibitors | Upstream TFEB | None in neurodegeneration | Oncology focus |
| University labs | TFEB gene therapy | AAV-TFEB OE | PD | Preclinical |

Observation: No major pharmaceutical company is actively pursuing TFEB activation for synucleinopathy. This represents an opportunity but also a risk—failure may reflect genuine tractability issues.

Safety Concerns

• mTOR inhibition: Immunosuppression (pneumonia risk), hyperlipidemia, glucose intolerance, wound healing impairment—acceptable for short-term transplant use, problematic for chronic neurodegenerative disease
• V-ATPase inhibition: Cytotoxicity from broad acidification blockade
• Trehalose failure: Likely due to inadequate CNS penetration rather than target failure—the hypothesis that lysosomal activation should work was sound, but the chemical matter could not achieve sufficient brain exposure

Cost and Timeline

Estimated preclinical investment: $15–25M over 24–30 months to identify a TFEB activator with CNS penetration and adequate therapeutic index

Key milestone: Demonstrate that TFEB activation rescues αS aggregation in PSEN2-mutant human iPSC neurons at drug concentrations achievable in vivo

Key risk: Trehalose failure suggests the pathway may require levels of activation or timing not achievable with small molecules. Gene therapy (AAV-TFEB) is an alternative but adds complexity and regulatory burden.

Hypothesis 6: p38 MAPK Inhibition — Mechanistically Coherent, Pharmaceutically Problematic

Is the Target Druggable?

Druggable at the kinase level, but p38α has been thoroughly validated as a poor clinical target for CNS indications. p38α MAPK is a well-characterized kinase with an ATP-binding pocket amenable to small molecule inhibition. The problem is not discoverability—it's the combination of toxicity, CNS penetration, and lack of selectivity over related kinases.

| Compound Class | Selectivity | Status |
|----------------|-------------|--------|
| First-gen (SB203580, SB202190) | Moderate | Research tools only |
| Second-gen (SB239063, RWJ67657) | Better | Preclinical/early clinical |
| Third-gen (Losmapimod/FWZ647) | High Kinase selectivity, moderate cellular | Phase II failed for cardiovascular; limited CNS data |
| PH-797804 | High | Phase II for COPD discontinued |

Existing Clinical Candidates

| Compound | Company | Highest Stage | Limitation |
|----------|---------|---------------|------------|
| Losmapimod | GlaxoSmithKline | Phase III (Fendy base) | Failed for acute coronary syndrome; inadequate CNS penetration for PD indication |
| MW150 | Miobx | Preclinical | Designed for CNS; selective for p38α over p38β; no published human data |
| Nelotanserin (MDI) | Arena/Roche | Phase I (abandoned) | Developed for CNS but for different indication |
| VX-745 | Vertex | Phase II (rheumatoid arthritis) | Discontinued; CNS penetration concerns |

Critical point: p38 inhibitors have repeatedly failed in late-stage clinical trials for peripheral inflammatory diseases. CNS indications compound the penetration problem.

Competitive Landscape

p38 inhibitors for neurodegeneration are essentially an abandoned competitive space:

• Eli Lilly pursued p38 inhibitors in the 2000s for Alzheimer's but did not advance
• GSK's losmapimod was tested in a Phase II study for ALS (NCT04057860) with negative results
• Array BioPharma/Corcept have programs but not in neurology
• No active clinical program testing p38 inhibition for synucleinopathies as of 2024

This is a significant risk signal. When multiple companies pursue the same target in neurodegeneration and all fail or abandon, the field is sending a message about tractability.

Safety Concerns

• Hepatotoxicity seen with multiple p38 inhibitors in clinical trials
• CNS adverse effects: Sedation, mood changes at higher doses
• Limited therapeutic window: p38α is expressed in neurons, microglia, and astrocytes—global inhibition affects all cell types with unpredictable net effect
• Redundant kinase pathways: CK1, CK2, PLK2, GRK2/3/6 all phosphorylate S129—blocking p38 alone is insufficient

Cost and Timeline

The path is higher risk and may require a new selective inhibitor:

Screen for selective p38α inhibitors with CNS penetration: ~$20–30M, 18–24 months

Optimize for neuronal p38α over microglial p38β/γ: Critical for efficacy/toxicity balance

Test in PSEN2 mutant iPSC neurons: Required validation step

Phase I start: Unlikely before 36 months from program initiation

Revised recommendation: Rather than pursuing p38 inhibition directly, consider upstream MAPKKK identification (e.g., MAP2K3/MAP2K6 knockdown) to achieve more selective pathway blockade. Alternatively, focus on the CK1δ isoform as an S129 kinase, which has better CNS penetration track record with compounds like LH-846 (in development for tau, not yet tested for αS).

Hypothesis 3: Calcineurin/NFAT Inhibition — Not Ready for Advancement

Is the Target Druggable?

Fully druggable at the protein level, but the chemical matter is toxic and the mechanism is poorly validated in neurons. Calcineurin is one of the most "druggable" targets in biology—cyclosporine A and FK506 are among the best-characterized drug-target interactions in pharmacology. The problem is that these compounds immunosuppress completely, precluding chronic use for neurodegeneration.

| Compound | Target | Status | Problem |
|----------|--------|--------|----------|
| Cyclosporine A | Cyclophilin A/CnA | FDA-approved (transplant) | Immunosuppression, nephrotoxicity, narrow therapeutic window |
| FK506 (Tacrolimus) | FKBP12/CnA | FDA-approved | Immunosuppression, neurotoxicity at high doses |
| Voclosporin | Cyclophilin A/CnA | FDA-approved (lupus nephritis) | Similar toxicity profile |
| Inhibitors of NFAT directly | NFAT calcineurin docking | Preclinical only | Peptidomimetic or highly charged compounds unlikely to enter CNS |

Competitive Landscape

| Company | Compound | Mechanism | Status |
|---------|----------|-----------|--------|
| No major company | — | Calcineurin/NFAT for neurodegeneration | Abandoned |
| Historical attempts | Cyclosporine A in traumatic brain injury | Neuroprotection (failed) | NCT001086768, negative result |
| Astellas/Roche | FK506 derivatives with reduced immunosuppression | Neuroprotective but FK506 scaffold limits utility | Discontinued |

The clinical signal is clear: Calcineurin inhibition has been tested in neurodegeneration contexts and failed, with unacceptable toxicity. The fundamental issue is that calcineurin has essential immune and non-immune functions in multiple organs—achieving selectivity for neuronal calcineurin over immune calcineurin has not been solved.

Safety Concerns

• Cyclosporine A: Nephrotoxicity (dose-limiting), hypertension, neurotoxicity (seizures), metabolic effects
• FK506: Neurotoxicity (post-operative delirium), nephrotoxicity, glucose intolerance
• Broader concern: Calcineurin-NFAT signaling is essential for T-cell activation, cardiac development, and vascular function. These cannot be separated from neuronal calcineurin with available chemistry.

Cost and Timeline

Do not advance without fundamental rescue data. Before any drug development investment:

Validate NFAT ChIP-seq in PSEN2 mutant vs. WT human neurons (6–12 months, $150–300K)

Demonstrate that calcineurin shRNA or CaN overexpression bidirectionally regulates SNCA mRNA in PSEN2 neurons (3–6 months)

Only if validated: pursue selective neuronal CaN inhibitors (novel chemistry required, likely 36+ months and $40–60M)

Bottom line: This hypothesis requires too many fundamental unknowns resolved before investment is justified.

Lower-Confidence Hypotheses: Quick Practically Grounded Assessment

Hypothesis 2 (AICD-AP-1): Not Actionable

• AICD is transient, not a viable small molecule target
• No pharmacological tool to selectively modulate nuclear AICD exists
• Even if valid, would require nuclear-targeted γ-secretase modulators with preserved AICD generation
• Recommendation: Deprioritize; pursue only if mechanistic validation shows SNCA as a direct AICD target

Hypothesis 4 (β-amyloid/actin/exosome): Premature

• Rests on an unreplicated preprint (PMID:38496508)
• No selective pharmacological approach to β-amyloid/actin/exosome axis
• Anti-Aβ antibodies (BAN2401, Lecanemab) are in trials but their mechanism does not align with this hypothesis—they target extracellular Aβ, while this model implies intracellular/pathological exosomal Aβ
• Recommendation: Wait for preprint replication; if replicated, prioritize RAB27A as the most druggable node (small molecule RAB27A modulators in oncology literature)

Hypothesis 5 (ERAD): Pharmacologically Tractable But Mechanistically Weak

• ERAD enhancers exist (e.g., Geldanamycin derivatives, NVP-BGT226, compounds targeting p97/VCP)
• XBP1s activators have been explored (luminescence-based screens)
• The fundamental problem: αS is not an established ERAD substrate—without this foundational validation, ERAD enhancers will not work
• Recommendation: Test whether αS is retrotranslocated in an ERAD assay before investing in compound screens

Hypothesis 7 (PSEN2/LRRK2/Rab35): Interesting but Premature for Drug Development

• LRRK2 inhibitors are in active clinical development (LRRK2-IN-1, DNL151/BIIB122 by Denali/Biogen is in Phase I/II for Parkinson's)
• However, the scaffold hypothesis does not directly enable use of LRRK2 inhibitors—inhibiting LRRK2 in PSEN2 loss-of-function may not restore Rab35-dependent trafficking
• Direct Rab35 modulators are essentially nonexistent as chemical matter
• Recommendation: Establish whether PSEN2-LRRK2 physical interaction is necessary for Rab35 phosphorylation before pursuing pharmacologically

Prioritization Framework for Investment

Based on synthesis of mechanistic confidence, drug development feasibility, and competitive landscape:

| Rank | Hypothesis | Investment Priority | Rationale |
|------|------------|-------------------|-----------|
| 1 | TFEB activation | Advance | Most druggable axis, autophagy-lysosome link is established independent of PSEN2 mechanism; trehalose failure means new chemical matter needed |
| 2 | p38 MAPK | Conditional | Mechanistically sound but requires new CNS-penetrant selective inhibitor; MAPKKK upstream approach more tractable |
| 3 | LRRK2/Rab35 | Conditional | Leverages existing LRRK2 inhibitor programs; needs scaffold validation first |
| 4 | β-amyloid/actin | Wait | Pending preprint replication; if validated, RAB27A is most druggable node |
| 5 | Calcineurin/NFAT | Do not advance | Mechanism not validated in neurons; existing inhibitors are too toxic |
| 6 | ERAD | Do not advance | αS is not established as ERAD substrate |
| 7 | AICD-AP-1 | Do not advance | Not pharmacologically tractable; mechanism disputed |

Key Gaps Requiring Resolution Before Investment

Critical path experiments by priority:

PSEN2-specific TRPML1/lysosomal calcium: Confirm that PSEN2, not PSEN1, drives the TRPML1 axis in human neurons (6 months, $200K)

TFEB endogenous activation: Demonstrate that TFEB nuclear translocation at endogenous expression is impaired in PSEN2 mutant neurons—not overexpression rescue (3 months, $100K)

NFAT neuronal ChIP-seq: Establish whether SNCA is an NFAT target in human cortical neurons (6 months, $150K)

Preprint replication (PMID:38496508): β-amyloid-actin-PSEN2 module requires independent replication before Hypothesis 4 investment (variable cost)

If all four return positive: Strong basis for TFEB activator program with estimated $25–40M and 30–36 month path to IND.

Practical Recommendation

The most defensible investment is a TFEB activator program with a defined chemistry strategy that addresses trehalose's failure: achieving CNS penetration with a compound that activates TFEB without the metabolic liabilities of rapamycin. This likely means either:

Lysosomal V-ATPase modulators with improved selectivity (beyond bafilomycin)

Genistein analogs with optimized CNS penetration

Direct TFEB agonists discovered via high-throughput TFEB nuclear translocation assay

The p38 program is a secondary option if a selective CNS-penetrant inhibitor with a favorable safety profile can be identified through a novel chemical series, or if upstream pathway targeting (MAP2K3/6) proves more selective.

Calcineurin, ERAD, and AICD hypotheses should not receive investment until fundamental mechanism rescue data are generated in human neurons.